Tag - PROF

Developments

Study finds invasive prostate cancer incidence rising among young men

The incidence of prostate cancer among adolescents and young adults has increased in the U.S. and many other countries during the past three decades, in direct contrast to older men, according to study results published...

November 20, 2019

Markets

Paradigm ups Profound Medical PT to C$45

Paradigm Capital raised its price target for Profound Medical (TSX:PRN; NASDAQ:PROF) to C$45 from C$40 based on the company’s commercialization plan for TULSA-PRO. The stock closed at $12.70 on the TSX on Nov. 5...

November 6, 2019

Developments

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...

April 12, 2019

Developments

Profound Medical posts positive top line pivotal trial results in prostate cancer with TULSA-PRO

Profound Medical (TSX:PRN; OTCQX:PRFMF) reported positive top line results from the TACT pivotal study designed to support its application to the FDA for 510(k) clearance to market TULSA-PRO in the U.S. The TULSA-PRO...

April 5, 2019

Markets

Paradigm ups Profound Medical PT to $3

Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20. “We see this...

March 21, 2018

Markets

Profound Medical closes upsized bought deal financing

Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option. Net proceeds are expected to be...

March 20, 2018

Tag - PROF

Study finds invasive prostate cancer incidence rising among young men

Paradigm ups Profound Medical PT to C$45

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Profound Medical posts positive top line pivotal trial results in prostate cancer with TULSA-PRO

Paradigm ups Profound Medical PT to $3

Profound Medical closes upsized bought deal financing

General

More